Promising preliminary results from phase II trial reiterate value of FUS as a promising therapy on the horizon for Drug-resistant Epilepsy
Dr. Yu Hsiang-Yu, Director of the Epilepsy Department at Taipei Veterans General Hospital Neurological Center, held a press conference earlier today summarizing the results of the previous pilot clinical trial using focused ultrasound (FUS) to treat patients with epilepsy and promoting the follow-up study that is currently underway.
The studies utilize NaviFUS’ FUS device, which can emit low-intensity FUS pulsations to non-invasively penetrate the human skull and modulate nerve conduction signals (such as epileptic seizure symptoms) without causing adverse side effects such as radiation damage, infection, bleeding, and tissue destruction.
Dr. Yu stated that results from the trials are promising, and she also believes low-energy focused ultrasound neuromodulation will be a feasible treatment for epilepsy in the future. The follow-up next-phase study already has collected some preliminary data and is currently recruiting patients. NaviFUS’ FUS device has also garnered interest from the international academic community for collaboration at many prestigious institutions around the world.
View source version on：
台北榮總發表頑性癲癇治療新曙光「聚焦式超音波」(udn.com)